Location and character of volatile general anesthetics binding sites in the transmembrane domain of TRPV1 by Jorgensen, Christian & Domene, Carmen
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1021/acs.molpharmaceut.8b00381
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Jorgensen, C., & Domene, C. (2018). Location and character of volatile general anesthetics binding sites in the
transmembrane domain of TRPV1. Molecular Pharmaceutics.
https://doi.org/10.1021/acs.molpharmaceut.8b00381
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
 1
Location and character of volatile general anesthetics binding sites in the 
transmembrane domain of TRPV1 
 
Christian Jorgensena and Carmen Domenea,b,c,* 
aDepartment of Chemistry, Britannia House, 7 Trinity Street, King’s College London London SE1 1DB, UK, bDepartment of 
Chemistry, University of Bath, 1 South Building, Claverton Down, Bath BA2 7AY, UK, CChemistry Research Laboratory, 
Mansfield Road, University of Oxford, Oxford OX1 3TA, UK  
 
*Corresponding author: C.Domene@bath.ac.uk  Tel: +44 - (0)1225-386172 
Abstract 
It has been proposed that general anesthesia results from direct multisite interactions with multiple and 
diverse ion channels in the brain. An understanding of the mechanisms by which general anesthetics 
modulate ion channels is essential to clarify their underlying behavior and their role in reversible 
immobilization and amnesia. Despite the fact that volatile general anesthetics are drugs that primarily 
induce insensitivity to pain, they have been reported to sensitize and active the vanilloid-1 receptor, 
TRPV1, which is known to mediate the response of the nervous system to certain harmful stimuli, and 
which plays a crucial role in the pain pathway. Currently, the mechanism of action of anesthetics is 
unknown and the precise molecular sites of interaction have not been identified. Here, using ~2.5 µs of 
classical molecular dynamics simulations and metadynamics, we explore these enigmas. Binding sites 
are identified and the strength of the association is further characterized using alchemical free-energy 
calculations. Anesthetic binding/unbinding proceeds primarily through a membrane-embedded 
pathway, and subsequently, a complex scenario is established involving multiple binding sites featuring 
single or multiple occupancy states of two small volatile drugs. One of the five anesthetic binding sites 
reported was previously identified experimentally, and another one importantly, is identical to that of 
capsaicin, one of the chemical stimuli that activate TRPV1. However, in contrast to capsaicin, 
isoflurane and chloroform binding free-energies render modest to no association compared to capsaicin, 
suggesting a different activation mechanism. Uncovering chloroform and isoflurane modulatory sites 
will further our understanding of the TRPV1 molecular machinery and open the possibility of 
developing site-specific drugs. 
 
Keywords:  
anesthesia; molecular dynamics simulations; docking; funnel metadynamics; TRP channels 
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Introduction 
It has been proposed that general anesthesia results from direct multisite interactions with multiple and 
diverse ion channels in the brain.1 Experimental findings of volatile general anesthetics binding to ion 
channels comes from structural work, where crystal structures of membrane proteins were obtained in 
complex with volatile general anesthetics,2-5 as well as mutagenesis6 and photolabelling7 studies. In 
particular, evidence of a modulation mechanism for anesthetics on both the nAChR (nicotinic 
acetylcholine) and GABAA receptors involving multiple binding sites has been described 
experimentally.8-10 In parallel, computational studies have yielded insights into volatile general 
anesthetics binding in membrane proteins,11-14 including simulations using a supersaturated isoflurane 
concentration suggesting that the modulation of nAChR and GLIC ion channels, occurs by binding to 
multiple sites.11 In sodium channels, microsecond simulations of NavAb revealed a similar multiple-
binding site model for local anesthetics benzocaine and the anti-seizure drug phenytoin, and yielded two 
drug-access pathways into the pore, a lipophilic access pathway through lateral fenestrations, and an 
aqueous pathway through the intracellular activation gate for local anesthetic benzocaine12 as well as 
volatile general anesthetics isoflurane and sevoflurane, which have been shown to modulate the gating 
of the prokaryotic Na+ channel NaChBac by increasing forward activation rates.15-16 At present, there is 
growing evidence that most general and local anesthetics as well as some analgesics also activate or 
sensitize nociceptors via TRPA1 or TRPV1 ion channels.17-18 Recently, a putative binding site for the 
general anesthetic propofol  has been identified in the TRPA1 ion channel using mutagenesis studies,19 
near the cavity lined by residues S876, M915, and M956 from the S5 and S6 transmembrane helices. 
Further work by photolabeling has yielded supporting evidence for this site, highlighting the residues 
the V954 and E969 from the S6 transmembrane helix as crucial in the activation of TRPA1 by 
propofol.20 Activation and sensitization of TRPV1 induced by local anesthetics is thought to involve a 
domain that is similar but not identical to the vanilloid-binding domain, the area of the protein that 
interacts with its agonist.17 
Volatile general anesthetics (VGAs) span a group of chemicals that are able to reversibly inhibit the 
central nervous system activity, rendering patients unresponsive to stimuli in contrast to local 
anesthetics. Little is known about the molecular targets of inhaled anesthetics to relate their effect to 
pharmacology. However, their binding sites are known to be hydrophobic with some polar character 
and with sufficiently general features to be widespread.21 Volatile general anesthetics including 
isoflurane (1,1,1-trifluoro-2-chloro-2-(difluoromethoxy)-ethane), chloroform, propofol, and halothane 
are reported to bind directly to ion channels.3-4, 22-23 In contrast to their inhibitory effects on the central 
nervous system, several volatile general anesthetics are known to activate or sensitize the signaling of 
peripheral nociceptive (pain-sensing) neurons24 which gives origin to their pungency or the condition of 
having a strong and sharp smell or taste that can be unpleasant.  
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The transient receptor potential (TRP) ion channels constitute a large and diverse family of non-
selective cation channels, found in yeast and widespread in the animal kingdom.25 These channels are 
expressed in excitable and non-excitable cell tissue, playing a critical role in sensory physiology by 
acting at the cell level, including synaptic activity or hormone secretion, and at organism levels (tactile, 
hearing, taste, olfaction, vision and thermal sensation).25-26 TRP channels display multifunctional and 
polymodal behavior in their regulation and interactions. In particular, the vanilloid-1 channel (TRPV1), 
arguably the best-characterized member of the vertebrate TRP family, is activated by a diverse array of 
physical and chemical stimuli such as noxious heat, inflammatory agents, such as extracellular protons 
and lipids, or capsaicin, the active compound of chili peppers that elicits burning pain.27 Upon capsaicin 
stimulation, the channel undergoes pore dilation, in which its selectivity for large cations over sodium 
ions is increased. While a single capsaicin-bound subunit was sufficient to achieve maximal open-
channel lifetime, all four proton-binding sites were required. Therefore, the pain receptor TRPV1 was 
reported to display agonist-dependent activation stoichiometry.28  
Chloroform became the most popular volatile general anesthetic of the 19th century, before being 
abandoned because of its low therapeutic index,23 but has recently regained interest as having been 
reported to activate the TRPV1 ion channel at millimolar concentrations using a similar mechanism as 
isoflurane. In particular, experimental data has suggested that TRPV1 is directly activated by 
chloroform, and none of the other heat-activated channels (TRPV2, TRPV3 or TRPV4) are activated by 
chloroform at clinical concentrations that are reported to elicit a robust activation of TRPV1.23 
Chloroform at a concentration of ~6.3 mM had solely an additive effect on channel activation when 
administered in the presence of capsaicin concentrations of ≤5 nM, while at concentrations ≥10 nM 
capsaicin yielded indistinguishable activation in the presence or absence of chloroform.23 It has been 
postulated that residue E600 is required for proton and volatile general anesthetics activation, and Y653 
is required for heat and volatile general anesthetics activation of TRPV1,23 and that these two residues, 
E600 and Y653, might facilitate channel activation.29 Recent structural and biophysical studies have 
resolved the atomic structures of some of the members of the TRP family primarily by cryo-electron 
microscopy.27, 29 These structural models provide an excellent starting point for the mechanistic study of 
anesthetic interactions and binding at the molecular level.  
From the cryo-EM structure, the TRPV1 channel architecture consists of a tetrameric assembly of four 
monomeric subunits, analogous to those of voltage-gated sodium and potassium channels. Each subunit 
consists of six trans-membrane α-helices (S1–S6) and an S5-P-S6 pore loop–helix (Figure 1.A). 
Previously, computational studies reported cation binding sites in the pore domain of TRPV1,30,31 in 
particular confirming the capsaicin binding poses (Figure 1.A).32 Here, we attempt to explore the nature 
of the binding sites evoked by two volatile general anesthetics in TRPV1, chloroform and isoflurane 
(Figure 1.B), compare them with capsaicin, and narrow down putative interaction sites hinted in 
experimental studies. The system setup is represented in Figure 1.C. 
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Figure 1. (A) Two TRPV1 subunits shown in blue and white, respectively indicating the site where capsaicin binds reported 
in structural studies.32 Capsaicin is shown in licorice representation, and the structural elements of one of the monomers are 
labelled (helices S1 to S6 and P-loop connecting helices S5 and S6). (B) Chemical structure of capsaicin, isoflurane and 
chloroform respectively. (C) Simulation setup for the TRPV1 transmembrane region embedded in a POPC membrane shown in 
green, and with an initial random distribution of volatile anesthetics in solution in the bulk. 
Materials and Methods 
System set-up 
The atomic model of the apo open-activated state of the transmembrane region of the vanilloid receptor 
1 (TRPV1) was retrieved from the protein data bank, PDB ID 3J5Q,29 at resolution 3.4 Å (residues 
V430 to V686). The set-up was done with CHARMM-GUI (http://www.charmm-gui.org).33 The N-
terminus was acetylated and the C-terminus was methylated. The CHARMM36 force field with CMAP 
corrections was used for the protein34-35 and lipids36 together with the TIP3P model for water 
molecules.37 CHARMM force field parameters for isoflurane38 and chloroform39 were used. Default 
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ionization states were used for the protein on the basis of PropKa calculations.40 The protein was 
embedded in a pre-equilibrated lipid bilayer of 240 POPC (1-palmitoyl, 2-oleoyl-sn-glycero-3-
phosphocholine) lipids using the replacement method of CHARMM-GUI, with 120 lipids in the upper-
layer, and 120 lipids in the lower layer, with the axis aligned to the bilayer normal. The system was 
embedded in a rectangular water box of dimensions (110, 110, 85) Å3. A 150 mM KCl solution was 
added to neutralize the system. The full TRPV1 pore system (residues V430-V686) comprised ~90,000 
atoms, while the pore model (E570-V686) comprised ~50,000 atoms. The total concentration of 
isoflurane and chloroform added independently was 8 mM to facilitate sufficient statistics. 
Equilibration was done using NAMD version 2.941 starting with 5,000 steps of steepest-descent 
minimization, 75 ps of dynamics in the NVT ensemble with restraints on the backbone with a time-step 
of 1 fs, followed by 300 ps of dynamics in the NVT ensemble with restraints on the backbone with a 
time-step of 2 fs. Finally, the system was evolved 1.0 ns in the NPT ensemble. The output of the MD 
equilibration was used as the starting point for two subsequent sets of MD production runs with (i) 40 
isoflurane or (ii) 40 chloroform molecules (Figure 1.C). Production runs of the flooding simulations 
were performed in the NPT ensemble. A summary of the simulations performed is reported in the 
Supplementary Material Table S1. The particle mesh Ewald (PME) algorithm was used for the 
evaluation of electrostatics interactions beyond 12 Å, with a PME grid spacing of 1Å, and NAMD 
defaults for spline and κ values.42 A cut-off at 12 Å was applied to non-bonded forces. Both 
electrostatics and Van der Waals forces were smoothly switched off between the cut-off distance of 12 
Å and the switching distance of 10 Å, using the default NAMD switching function. A Verlet neighbor 
list with pairlist distance of 16 Å was used to only evaluate non-bonded neighboring forces within the 
pairlist distance 43. The lengths of covalent bonds involving hydrogen atoms were constrained by the 
SETTLE algorithm 44 in order to be able to use a 2-fs time-step. The multi time step algorithm Verlet-
I/r-RESPA43, 45 was used to integrate the equations of motion. Non-bonded short-range forces were 
computed for each time step, while long-range electrostatic forces were updated every 2 time steps. The 
pressure was kept at 1.013 atm by the Nosé-Hoover Langevin piston46-48 with a damping time constant 
of 25 fs and a period of 50 fs. The temperature was maintained at 303.15 K by coupling the system to a 
Langevin thermostat, with a damping coefficient of 1 ps-1. 
Anesthetic binding sites from volumetric data maps 
Anesthetic binding sites in the two 500-ns simulations were characterized from volumetric data maps of 
isoflurane and chloroform occupancy calculated with the Volmap tool of VMD.49 This tool calculates 
volumetric maps, which are 3D grids that have a value assigned at each grid point, based on the atomic 
coordinates of a specified atom selection using either a density or occupancy criterion. In occupancy 
maps, each grid point is assigned to be 1 if it contains one or more atoms of the selection or 0 if it does 
not. When averaged over all the frames of the trajectory, this map contains the fractional occupancy of 
that grid point. Here, occupancy maps were calculated based on the selection of all 40 isoflurane or 40 
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chloroform molecules respectively from each frame, and were averaged over the entire trajectory. The 
fractional occupancy out of 100% was represented as iso-20% contour surface maps in Figures 3 and 4. 
Free energy of insertion of anesthetics in the membrane 
In order to estimate the partition free energies of isoflurane and chloroform in the membrane, estimates 
of the free energy of insertion in the POPC lipid bilayer were calculated using metadynamics50 with a 
funnel-restrained potential,51 enabling the exploration of both the unbound bulk and lipid-partitioned 
states. An equilibrated bilayer of 100 POPC molecules with just one anesthetic molecule was set up, 
with a 0.15 mM background KCl. A funnel-restrained well-tempered metadynamics50 calculation using 
the collective variable ξ1 as the distance along the Z-axis was used, where ξ1 = 0 Å constitutes the 
membrane centre and ξ1=35 Å is the bulk solution. In addition, ξ2 is the radial distance of the drug in 
the funnel, as measured from the Z-axis which corresponds to the transversal funnel degree of freedom. 
This simulation was performed using Plumed 1.352 with NAMD 2.9, with a Gaussian of width 0.2 Å 
and initial height 0.12 kcal/mol deposited every 1 ps using a bias factor of 12. The funnel-restrained 
potential is a combination of a cone restraint which includes the external side of the membrane, and a 
cylindrical part which is directed toward the solvent.51 The alpha angle, α, denoting the funnel angle 
from the normal axis was set to 0.55 rad (31.5°) and Zcc the funnel height was set to 35 Å, placed at the 
center of the membrane. A geometric correction term (Equation 1) is added to the free-energy, ∆G, to 
give the free-energy of translocation from the bulk to the membrane, ∆G°, by computing the geometric 
contribution from the bulk cylinder of radius Rcyl = 1 Å, scaled by the standard concentration C
0 = 1 mol 
dm-3 = 1/1661 particles Å-3.  
∆Go = ∆G −
1
β
ln πRcyl
2 Co( )     Equation 1 
An error analysis was performed to obtain the fluctuation in the ∆G for the translocation between 
aqueous and membrane phase by calculating the time evolution of the ∆G between the aqueous (25 Å 
<ξ<30 Å) and the membrane center (7 Å <ξ<12 Å) potential of mean force. This value was averaged 
for the plateau which corresponds to the last 100 ns of the simulation, and a standard deviation is 
reported such that the translocation is ∆G ± σ. 
Standard free energy of binding of anesthetics to TRPV1 
The free energy of binding, ∆Gbind, of each anesthetic to TRPV1 was calculated and compared to the 
binding energy of the TRPV1 agonist capsaicin,32 starting from the pose observed when bound in site 
II’. The value of the free energy of binding of capsaicin to TRPV1 was reported32 to be -10.6 ± 1.7 kcal 
mol-1 obtained using the method by Gumbart et al.53 A schematic representation of the cycle is 
presented in Figure S1.A and shown exemplified by isoflurane in Figure S1.B. This method gives the 
change in the free energy of binding, ∆Gbind, but does not reveal the cost of translocating the anesthetic 
to the binding site, and the method relies upon alchemical free-energy perturbation transformations 
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combined with geometrical restraints on the anesthetics to avoid the wandering ligand problem at the 
end of the decoupling or beginning of coupling simulations.54-55 Reversible coupling of the anesthetic to 
its environment, either coupling to the TRPV1 pocket (bound) state or decoupling in the bulk aqueous 
solution (unbound state) was performed bi-directionally using the free energy perturbation (FEP) 
method. The order parameter λ was evenly divided into 16 windows of width equal to 0.05 in the range 
0.1 to 0.9, plus 40 windows of width equal to 0.005, in the range 0 to 0.1 and 0.9 to 1.0. Each window 
consisted of 200,000 data collection steps (0.4 ns) proceeded by 50,000 equilibration steps (0.1 ns). The 
total simulation time was 28 ns per coupling/decoupling cycle, totaling 54 ns for the bound state and 54 
ns for the unbound state. The total simulation time employed for the alchemical FEP calculations was 
216 ns.  
The convergence of the alchemical calculations was evaluated by analyzing the overlap of the ∆U 
distributions for the forward (∆U0) and backward (∆U1) calculations, per window (Figure S2). The 
statistical data was combined by means of the Bennett acceptance ratio (BAR)56 which provides a 
maximum-likelihood estimator of the free-energy change.57 The ParseFEP tool58 implemented in 
VMD49 was used to analyze the results. To prevent the wandering ligand problem, the conformation of 
anesthetic was restrained during the free-energy calculations and each calculation was based on the 
central cluster node from the MD binding site II” (capsaicin binding site) occupied in one of the four 
TRPV1 subunits. Geometrical restraints were defined based on three invariant protein reference sites 
(P1, P2, P3). These sites were defined as the center of mass (COM) of heavy atoms of residues A566, 
F582 and L664. In addition, three reference sites in the anesthetic molecules (L1, L2, L3) were defined. 
These sites correspond to the center of mass of selected pairs of atoms in isoflurane or chloroform. In 
total, six sites were used to define the harmonic restraints ur (distance P1−L1), uθ (angle P2−P1−L1), 
and uφ (dihedral P3−P2−P1−L1) used to fix the position of the anesthetic molecule in the protein 
pocket. UΘ (angle P1−L1−L2), uΦ (dihedral P1−L1−L2− L3), and uΨ (dihedral P2−P1−L1−L2) were 
used to fix the anesthetic orientation. Finally, a harmonic RMSD restraint on the conformation of the 
anesthetic molecule (uc) ensured the pose was fully fixed. To estimate the contribution to the free energy 
of binding as a result of the restraints, thermodynamic integration (TI) simulations were performed 
coupling the force constant of each harmonic potential to the order parameter λ in a 12-point grid. The 
gradient of the potential energy with respect to the collective variable was calculated from MD 
simulations at each value of λ. Each simulation consisted of 200,000 data collection steps (0.4 ns), after 
50,000 steps (0.1 ns) of equilibration. Scaling of the force constants was also performed bi-
directionally, and the free energy contribution of the restraints was retrieved averaging both 
contributions. The error was estimated as the maximum hysteresis between forward and backward 
calculations. 
Docking procedure 
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Docking of anesthetics was performed using Autodock (v4.2) on the full TRPV1 pore (V430-V686).59 
Two dockings were performed, one based on the holo-TRPV1 trajectory (PDB id 3J5Q; Resolution 3.8) 
and the second based on an apo-TRPV1 trajectory (PDB id 3J5P; Resolution 3.4 Å). For trajectories of 
either the apo or holo system, the first 50 ns of equilibration were discarded after inspections of the 
protein backbone RMSD plot. Subsequently, 500 snapshots at intervals of 0.2 ns were extracted for 
docking from the holo system, and 300 snapshots at intervals of 0.2 ns from the apo system. A global 
search was carried out with a large box centered on the protein and employing 140 x 140 x 110 grid 
points with default grid spacing of 0.375 Å. For each docking snapshot, 10 solutions were requested. 
Altogether, 5,000 and 3,000 docking poses were generated respectively, which were later clustered 
according to the RMSD of the ligand using a RMSD < 2.5 Å criteria per cluster. 
Results 
Partition of anesthetics in the lipid bilayer 
An interaction between inhalational anesthetics and proteins was first suggested by Claude Bernard in 
1875,60 and subsequently by Moore and Roaf  in 1904 and 190561-62 (see reference [21] for a detailed 
historical account). In contrast, Meyer, Overton, and others, proposed that the lipid membrane of the 
cell was generally to be the primary site of action of anesthetics.63-64 Recent work continues to suggest a 
membrane-mediated mechanism whereby chemical compounds may modify the properties of the cell 
membrane, which in turn, would alter the properties of the proteins embedded in the cell membrane. 
Alternatively, anesthetics would need to cross the water-membrane interphase until they reach specific 
sites in the protein and as a result of these interactions the protein gating and permeation properties will 
be altered. Currently, the favoured hypothesis proposes that general anesthesia results from direct 
multisite interactions with multiple and diverse ion channels in the brain as gradually a number of 
important molecular targets have emerged. In this respect, how volatile general anesthetics act at the 
molecular level is becoming clearer. 
Two 0.5-µs MD flooding simulations of either isoflurane or chloroform partitioning into a fully 
solvated TRPV1 transmembrane domain inserted in a POPC bilayer were performed. Partitioning 
events observed are reported in Figure 2 and a description of the binding sites to TRPV1 in Figure 
3.The free energy of translocation is reported in Figure 4, and the free-energy of membrane partitioning 
from metadynamics is reported in Figure 5. Overall, the protein is stable during the simulation time 
even in the presence of a high concentration of anesthetics as illustrated from the analysis of the protein 
all-atom backbone root-mean-square deviation that renders values of 2.2 ± 0.2 Å and 2.7 ± 0.3 Å with 
fluorine and cholesterol respectively (Supplementary Material Figure S3 and Table S1). These values 
are within the resolution of the model structure employed indicating that equilibration was achieved. 
Chloroform and isoflurane can affect the TRPV1 ion channel by partitioning into the plasma membrane, 
a process facilitated by hydrophobic interactions with the inner-membrane core, and then can modify 
the properties of the bilayer, or alternatively, they can reach the transmembrane region of the protein 
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and compete with capsaicin and other activators. In this context, while both chloroform and isoflurane 
have moderate lipophilicity65 (logP 2.0 and 2.1, respectively), chloroform possesses a dipole moment 
(9.5 Å3) and has been found to display a slight preference for the membrane core.66 Isoflurane, in 
contrast, is a non-hydrophobic anesthetic38, 67 which readily partitions into the lipophilic phase, but 
shows a preference for the interfacial regions, with some studies suggesting that it does not readily 
accumulate in the hydrophobic membrane core.11, 68 The behavior of other TRPV1 agonists such as 
camphor (logP 2.2) is similar to isoflurane showing preference for the interface which means its 
therapeutic dose is higher than that for other agonists.69 Strikingly, despite the relatively high 
concentration required for activation and potentiation of TRPV1, the effects of camphor were found to 
be rapidly and readily reversible and a mechanical rather than a biochemical link to the pore gating 
machinery was proposed.69 
In the current study, both anesthetics partition readily into the membrane phase (Figure 2.A) reaching 
95% and 90% for isoflurane and chloroform respectively after 200 ns of simulation time (Figure 2.B). 
No distortion of the lipid membrane was observed upon partitioning as had already been reported in 
earlier simulations of isoflurane and similar VGAs.70 On the whole, the lipophilic entry route is the 
primary access mode for these anesthetics to the protein binding sites as illustrated for two diffusion 
pathways of membrane-partitioned isoflurane and chloroform monitored by the ligand RMSD over 
trajectory time (Figure 2.C) and depicted as iso-contour trajectory probability in Figure 2.D. Only 5% 
of isoflurane molecules and 10% of chloroform do not reach their binding sites via membrane 
partitioning. The secondary pathway (Figure 2.A) is a direct entry into the protein from the bulk (Figure 
2.A). 
 
Figure 2. (A) Schematic comparison of the lipophilic and aqueous entry routes into the site II’. The lipid membrane is 
depicted in grey color and one out of the four monomers composing the transmembrane domain of the ion channels is depicted 
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in ribbon representation with each transmembrane helix colored differently. (B) Percentage (%) of anesthetics partitioning into 
the membrane for isoflurane (color code blue; plateau 95%) and chloroform (color code red; plateau 90%) as a function of 
simulation time. (C) Evolution of the ligand RMSD with respect to its bound pose in the capsaicin site (II’) for two isoflurane 
(blue) and two chloroform (red) molecules. Each molecule is labeled 1 or 2. (D) Illustration of the entry pathway through the 
membrane observed for each of the two chloroform and isoflurane molecules considered, looking from above the lipid 
membrane and indicated by arrows. Please note that this illustration was produced from a superposition of frames from two 
independent simulations. 
Upon reaching the inner transmembrane region, five binding sites were identified using iso-contour 
projections (Figure 3.A and B): (a) a pore site, site I (Figure 3.C), (b) the same site capsaicin occupies, 
site II’ (Figure 3.D), (c) two side-pocket sites II and III, and finally (e) site IV, within the outer helices 
(Figure 3.E). The protein-anesthetic contacts identified are described in detailed in Table S2 and are 
graphically summarized in for three key sites (Figure 3.C,D,E). The binding sites were validated by 
projections of the chloroform free-energy surface (Figure 4.A) compared to the iso-contour probabilities 
(Figure 4.B) and the same for isoflurane (Figure 4.C to 4.D). The stability of the binding poses is 
characterized by the ligand root mean square deviation relative to the binding pose in each site, as 
illustrated for representative anesthetic trajectories in Figure 2.C and in full in Supplementary Material 
Figure S4. The difference in interactions between the protein and both anesthetics suggests chloroform 
and isoflurane bind differently to TRPV1. The difference can be ascribed to the smaller size of 
chloroform which allows for sampling regions that are not accessible to isoflurane, resulting in two 
additional sites accessible to chloroform, site II and III, which are variants of the side-pocket site II’ of 
capsaicin. Site II is flanked by helices S5, S6 and S6’ from a different subunit which resembles the 
propofol binding site recently reported for TRPA1.20 
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Figure 3. Population occupancy analysis for isoflurane (yellow) and chloroform (green) for the MD simulation using the full 
pore. (A) View of the system from the intracellular side in the XY plane, and (B) from a lateral perspective in the XZ plane of 
the membrane. Based on 500 ns of trajectory, an iso-0.2 contour criterion was employed for delimiting population, which 
shows iso-20% surfaces. (C, D, E) protein-anesthetic contacts within 4.5 Å distance cutoff, for key individual sites, in (C) for 
site I, (D) site II’ and (E) site IV.  
The iso-contour surfaces were used to generate a full probability distribution Z(ξ) of anesthetics during 
the MD simulations, which, when Boltzmann-weighted, give the free-energy surface (FES) projected 
onto the xy (ξ(x,y)) and xz (ξ(x,z)) planes: 
F(ξ) = -kT log (Z(ξ)/Z0)    Equation 2 
This final distribution illustrated in Figure 4.A and 4.C for chloroform and isoflurane respectively is 
comparable to the iso-probability contour surfaces of chloroform (Figure 4.B) and isoflurane (Figure 
4.D). Five binding sites are minima on the FES where the most long-lived binding sites (I, II’ and IV) 
are separated by up to 3 kcal mol-1 from the bulk. This result agrees with our estimate of binding free 
energy for chloroform and the free-energy gain for partition into the membrane. This projection also 
reveals the membrane-partitioned pathway to constitute a Minimum Free-Energy Path (MFEP) in 
agreement with the 4 kcal mol-1 binding affinity of local anesthetic binding benzocaine in flooding 
simulations of Nav channels when compared to the bulk configuration.12  
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Figure 4. Classification of anesthetics binding sites according to their free-energy maps. XY and XZ surface projections of the 
free energy surfaces (FES) from the intracellular side for (A) chloroform and (C) isoflurane. The construction of the maps is 
detailed in the Methods section. Binding sites are labelled from I to IV. The minimum free energy pathway from the bulk 
solution to the binding site is indicated with black arrows. Based on two 500-ns of trajectory, an iso-0.2 contour criterion was 
employed for delimiting populations which shows iso-20% occupancy surfaces illustrated for (B) chloroform (green) and (D) 
isoflurane (yellow) using a top or side view of the channel with respect to the membrane normal. 
The cost of moving isoflurane from the bulk solution to the polar head group interface of a POPC 
bilayer had previously been reported to be ≈4 kcal mol-1 using umbrella sampling simulations.70 Here, a 
0.8-µs well-tempered metadynamics simulation with funnel restraints was used to calculate the partition 
free energy from solution to the bilayer center. The restraint potential setup is given in Figure 5.A. The 
PMF for isoflurane and chloroform are reported in Figure 5.B, and the uncorrected ∆G of translocation 
obtained was -7.0 and -6.3 kcal mol-1 for isoflurane and chloroform respectively. A geometric 
correction term (Equation 1) of magnitude -3.7 kcal mol-1 was calculated which arises from the loss in 
conformational entropy in a bulk cylinder of radius Rcyl = 1 Å, and scaled by the standard concentration 
C0 = 1 mol dm-3 = 1/1661 particles Å-3. The resulting corrected free-energies (∆G°) were –3.3 and –2.6 
kcal mol-1 for isoflurane and chloroform respectively. Error bars were estimated by geometrically 
averaging the PMF at the plateau region in the last 100 ns of simulation. A standard deviation of 0.6 and 
0.8 kcal mol-1 for isoflurane and chloroform respectively is obtained. The final free energy of 
translocation, ∆G, between the bulk solution and the membrane center is -3.4 ± 0.6 and -2.5 ± 0.8 kcal 
mol-1 for isoflurane and chloroform respectively. 
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Figure 5. (A) Schematic funnel restraint setup. (B) Integrated 1D form of the potential of mean force (PMF) along ξ1 (Z-axis 
position) from metadynamics simulations with a funnel restraint, (C) evolution of collective variables ξ1 (Z-axis position) and 
(D) hills height. Upper panels correspond to isoflurane data and lower panels to chloroform data. 
From the detailed residue analysis illustrated in Figure 3.C, the anesthetic binding site I is flanked by 
two TRPV1 monomers and located at the pore (P)-loop region. Isoflurane and chloroform share two 
hydrophobic contacts when bound in Site I of TRPV1, L635 and I660 (Supplementary Material Table 
S2). In addition, isoflurane also interacts with another hydrophobic residue (F659), a polar residue 
(Y653) and two charged residues (E648 and K656). In contrast, chloroform interacts with three 
hydrophobic residues (F638, L647 and L663) and only one charged (K639) residue (Supplementary 
Material Table S2). This difference can be ascribed to the ability of isoflurane to form hydrogen bonds 
between the halogen and the hydroxyl group of the side-chain of Y653, among others. The same site 
was experimentally identified and reported in TRPV123 and it was highlighted that  residue E600 is 
essential for TRPV1 activation by protons and Y653 by heat and anesthetics. Isoflurane sampled 
extensively the same region reported experimentally, while chloroform diffused fast through the pore 
site, presumably aided by its smaller size. 
Site II’ is equivalent to the binding site described in the literature for TRPV1 activators,29 notably 
capsaicin. The pocket has dimensions of ~20 Å (E570-L662; Cα distance) by 12 Å (T550-I668; Cα 
distance), sufficient to accommodate the capsaicin molecule. In our simulations, this site is sampled by 
isoflurane and chloroform that reach the site via the lipophilic entry mechanism and a minor direct 
transition from the pore loop site I. The membrane-partitioned anesthetic diffuses into the Vanilloid 
Binding Pocket (Site II'), which in this state of TRPV1 is open and solvent-exposed. In one case, entry 
into Site II' occurs through initial hydrophobic guidance across the protein-membrane interface with 
residues V318 and F522 of the S2-S3 transmembrane helices. In another case, diffusion into Site II' 
occurs via the opening at Site II mediated by L585 and I668, located at the interface between the 
membrane and the protein intrasubunit lumen. Both anesthetics make contacts with amino acid residues 
M547 and A665. In addition, isoflurane interacts with Y511, L515, T550, I569, L573 and L669 
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(Supplementary Material Figure S5.A) while chloroform interacts with a reduced number of amino 
acids: F591, I668 and L673 (Supplementary Material Figure S5.B). Alignment was made with the 
docked poses of capsaicin from previous work,32 depicted in Fig. S5. In addition to structural overlap 
with capsaicin poses, an overlap of volatile general anesthetic contacts was observed with reported 
capsaicin contacts in TRPV132 for the down-conformation of capsaicin, Y511, L515, F543, M547, 
T550, A665, and L669, and for the up-conformation, Y511, L515, T550, F587, F591, I668, and L669. 
This site might constitute a potentiation or activation site of VGAs, akin to that of other TRPV1 
agonists. 
The side-pocket labelled site II located on the opposite side of the vanilloid binding pocket is flanked by 
the S4-S5 linker of one subunit, and the S6 P-loop of another subunit, similar to a propofol binding site 
reported for TRPA1.20 Chloroform makes contacts with Y584, F580, M581, L664, T670, and I672 
(Supplementary Material Table S2) while isoflurane sampled this site only transiently, moving into the 
adjoining site II’ where it resided for up to 400 ns. Side-pocket site III was only sampled by chloroform 
and is a short-lived site, with contacts with Y565, R579, F580, V583, L674, M677 (Supplementary 
Material Table S2). This site is located in the space between S5 and S6 helices both from one subunit, 
and is a metastable site connecting Site II’ of one subunit with Site II of another subunit (Figure 3). 
Finally, site IV is found in the space between helices S1, S2, S3 and S4, and is characterized by the 
presence of a majority of aromatic residues tyrosine and phenylalanine. Both isoflurane and chloroform 
make contacts with F488 and Y554. Isoflurane in addition interacts with Y441, Y495, F516, and N551, 
and a hydrogen bond can be formed between the isoflurane halogen atom and the hydroxyl hydrogen 
atom of Y495 and Y555, as well as hydrophobic interactions with the side chains of residues F488 and 
F516 (Supplementary Material Figure Table S2). Chloroform instead interacts with Y487, R491, F516, 
Y554 and Y555. The duration of these protein-ligand interactions is of hundreds of nanoseconds. 
Complementing the MD simulations, a blind docking search on 500 representative snapshots of the 
TRPV1 transmembrane domain obtained from the holo-TRPV1 trajectory with capsaicin bound32 
revealed that site II’ in the vanilloid binding pocket was the most populated (26.7% for isoflurane, 58% 
for chloroform) while the pore loop site I was the second hit (9% for isoflurane, 13% for chloroform), 
as detailed in the Supplementary Material Table S3. This blind docking search was repeated on a 
TRPV1 trajectory without capsaicin bound revealing that site II’ remained most populated for 
isoflurane (18%) while the pore loop site I became the most populated for chloroform (44.1%). These 
results suggest that anesthetics could indeed act as secondary TRPV1 agonists in the absence of 
capsaicin. 
It is known that binding of capsaicin induces activation in TRPV1 by stabilizing the open conduction 
state.29 The reported32 binding free-energy of capsaicin to TRPV1 is −10.6 ± 1.7 kcal mol-1. It has been 
found that isoflurane does not bind in this site, and chloroform does not bind as strongly as capsaicin 
but it does so with a modest association found to be -2.0 ± 0.8 kcal mol-1 (Supplementary Material 
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Table S4), corresponding to a binding constant Kd value of 36 mM. This suggests that the mechanism of 
action of anesthetics is different to the capsaicin mechanism of activation. It is known that volatile 
general anesthetics either activate or sensitize the channel to activation.24 Sensitization seems more 
probable from the weak association of anesthetics in Site II’. One crucial difference from capsaicin is 
the possibility of binding of more than one molecule of chloroform simultaneously in site II’. After one 
binding event, during the simulation, it is observed that a second chloroform molecule enters the site. 
Therefore, the binding of multiple anesthetics at this site could compensate for their weak binding 
affinity to enhance the sensitization effect on the channel. This is in agreement with recent work 
suggesting that small agonists do bind in a concentration-dependent manner in order to enhance their 
affinity as has been reported in the voltage-gated Kv1.2 ion channel.71 This can be partly explained due 
to their size, smaller than capsaicin, and their promiscuous binding poses. 
Discussion and Conclusions 
An understanding of the mechanisms by which general anesthetics modulate ion channels is essential to 
clarify the underlying behavior of ion channels and their role in reversible immobilization and amnesia. 
TRPV1 has distinct binding sites for its various agonists, and agonist binding is thus classed as 
allosteric. While capsaicin binds to the intracellular vanilloid binding side-pocket, protons bind to the 
extracellular outer-pore domain72-73 but both activate the channel.74 Allosteric activation occurs by 
preferentially stabilizing the open-activated conduction state over a closed-inactivated state. The exact 
stoichiometry of TRPV1 agonist binding probed from patch clamp experiments revealed that while a 
single capsaicin site is required to achieve a fully conducting TRPV1 pore, proton agonists require 
binding to all four subunits to exert activating effects.28 Currently, little is known about the sites at 
which drugs exert their influence. In addition, there is an ulterior motive for studying the interactions of 
volatile general anesthetics with TRPs which comes from the link between anesthesia and pain, and the 
observation that general anesthetics, through direct actions at TRP channels, increase postsurgical pain 
and inflammation.23, 75 In this study, we have focused on two general anesthetics chloroform and 
isoflurane; it has been reported that chloroform binds in dorsal root ganglion neurons to induce TRPV1 
activation while clinically relevant concentrations of isoflurane were shown to sensitize TRPV1 to 
capsaicin and protons and reduce its threshold for heat activation.75 Imaging studies also found that 
chloroform and isoflurane act cooperatively with other TRPV1 agonists to induce a shift in the thermal 
activation of TRPV1 toward lower temperatures in the presence of mM concentrations of them.75 At 
present, the general view is that chloroform and isoflurane could activate TRPV1 via similar 
mechanisms23 because they use overlapping sequence regions in the outer pore loop for activation, 
namely (i) residues required for proton and anesthesia activation (E600), and (ii) residues required for 
heat and anesthesia activation of TRPV1 (N628, N652, Y653).23 The mechanism of TRPV1 activation 
by anesthetics and the anesthetic interactions with TRPV1 remain unknown.  
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Translocation of anesthetics through the membrane from the bulk solution has been characterized by 
simulations with funnel-restrained metadynamics rendering a -3.4 ± 0.6 and -2.6 ± 0.8 kcal mol-1 cost 
for isoflurane and chloroform respectively. Once inside the membrane, anesthetics diffuse to the 
protein. In this study, the anesthetics binding sites found in TRPV1 share common traits with four 
binding sites reported for isoflurane in nAChR and GLIC channels: at the pore, inter-subunit, intra-
subunit, and annular sites,11 as well as common traits with up to seven sites identified for the local 
anesthetic benzocaine in a voltage-gated sodium channel (sites A to G).12 The site is flanked by the S6 
transmembrane helix and residue F203, and resembles the capsaicin site II’ reported here, as well as 
other six low affinities sites, including a pore site as well as an annular site in the outer transmembrane 
domain region (similar to the annular site IV described in this work). Our computational work supports 
a model where anesthetics occupy multiple sites with a total of five sites identified, in agreement with 
experimental studies.23, 75 It has been proposed that chloroform and isoflurane could activate TRPV1 via 
similar mechanisms23 by using overlapping regions in the pore loop site I. This is in agreement with 
reported studies showing that hydrophilic-polar interfaces bind volatile anesthetics.3-4, 22 Anesthetics 
access these sites from the bulk solution through the cell membrane by diffusion. Anesthetic 
partitioning converged after 0.2 µs with 95% of isoflurane and 90% of chloroform present in the 
membrane phase (Figure 2.B). The majority of bound anesthetic in TRPV1 entered through the 
lipophilic phase (100% of bound isoflurane, 92.5% chloroform), while a minority of events were 
observed for chloroform directly entering capsaicin site II’ from the aqueous phase (Figure 2.A). 
Finally, the way chloroform and isoflurane sample the inner-core of the protein is different. Chloroform 
is smaller than isoflurane, and can access easily inner-protein regions that were banned for isoflurane 
(sites II, and III) at least on the timescale of these simulations. 
Five binding sites for chloroform and three for isoflurane were characterized, the most long-lived of 
which are separated by up to 3 kcal mol-1 from the bulk (Figure 4.A and C). The simulations timescales 
employed here were sufficient to observe single binding and unbinding events for isoflurane and 
chloroform, but are not long enough to observe whether anesthetic binding is able to induce new 
conformational states as opposed to only bind to the pre-existing states employed in our simulations. 
These binding sites correspond to site II’ for chloroform and sites IV and II’ for isoflurane. Site I, in the 
outer pore, shares protein-ligand contacts with the experimentally determined outer pore loop activation 
site of TRPV1. The binding site of capsaicin in TRPV1 was also identified as an anesthetic site (Site 
II’), although alchemical free-energy calculations suggest modest to no association when comparing the 
free-energy of binding for anesthetics with the reported value for capsaicin which suggest an alternative 
activation mechanism. The difference between site I and capsaicin site II’ is the degree of 
hydrophobicity of each binding site. Site II’ is characterized by a hydrophobic, non-polar interface 
(L515, T550, I569, L573, A665, and L669), while the pore site I is characterized by a hydrophilic polar 
interface (E648, Y653, K656). The absence of significant structural rearrangements in the protein 
following anesthetic binding is consistent with the weak interactions that are involved. 
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The data presented here only provides information of the location of binding sites with moderate 
affinity as demonstrated by persistent occupancy, and does not describe the effect of anesthetics on the 
channel global dynamics that ultimately produce the behavioral response so-called anesthesia. 
However, atomistic information about where these drugs bind provides a first step in the understanding 
of how they allosterically modulate the function of this family of ion channels, in particular sensitize the 
channel to activation by capsaicin or heat, which could help inform further experiments to help 
understand ligand binding and aid to develop and screen for new drugs. 
Supporting Information. (1) Details of the MD simulation protocol; (2) RMSD profiles; (3) tables and 
distance profiles; (4) free-energy perturbation profiles and histograms. This material is available free of 
charge via the Internet at http://pubs.acs.org. 
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